184 related articles for article (PubMed ID: 21483840)
1. Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide.
Steinstraesser L; Hauk J; Schubert C; Al-Benna S; Stricker I; Hatt H; Shai Y; Steinau HU; Jacobsen F
PLoS One; 2011 Mar; 6(3):e18321. PubMed ID: 21483840
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic designer host defense peptide suppresses growth of human liposarcoma.
Steinstraesser L; Schubert C; Hauk J; Becerikli M; Stricker I; Koeller M; Hatt H; von Duering M; Shai Y; Steinau HU; Jacobsen F
Int J Cancer; 2011 Jun; 128(12):2994-3004. PubMed ID: 20734391
[TBL] [Abstract][Full Text] [Related]
3. Genotoxic and cytotoxic activity of host defense peptides against human soft tissue sarcoma in an in vitro model.
Steinstraesser L; Hauk J; Al-Benna S; Langer S; Ring A; Kesting M; Sudhoff H; Becerikli M; Käfferlein H; Jacobsen F
Drug Chem Toxicol; 2012 Jan; 35(1):96-103. PubMed ID: 21851146
[TBL] [Abstract][Full Text] [Related]
4. Effective oncolytic vaccinia therapy for human sarcomas.
He S; Li P; Chen CH; Bakst RL; Chernichenko N; Yu YA; Chen N; Szalay AA; Yu Z; Fong Y; Wong RJ
J Surg Res; 2012 Jun; 175(2):e53-60. PubMed ID: 22341347
[TBL] [Abstract][Full Text] [Related]
5. Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays.
Harati K; Behr B; Daigeler A; Hirsch T; Jacobsen F; Renner M; Harati A; Wallner C; Lehnhardt M; Becerikli M
Nutr Cancer; 2017; 69(2):340-351. PubMed ID: 28045549
[TBL] [Abstract][Full Text] [Related]
6. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.
Kawamoto M; Horibe T; Kohno M; Kawakami K
BMC Cancer; 2011 Aug; 11():359. PubMed ID: 21849092
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
8. The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor.
Shabahang M; Buffan AE; Nolla JM; Schumaker LM; Brenner RV; Buras RR; Nauta RJ; Evans SR
Ann Surg Oncol; 1996 Mar; 3(2):144-9. PubMed ID: 8646514
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent.
Kawamoto M; Kohno M; Horibe T; Kawakami K
Cancer Chemother Pharmacol; 2013 Mar; 71(3):799-807. PubMed ID: 23328867
[TBL] [Abstract][Full Text] [Related]
10. Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.
Harati K; Behr B; Wallner C; Daigeler A; Hirsch T; Jacobsen F; Renner M; Harati A; Lehnhardt M; Becerikli M
Mol Med Rep; 2017 Jan; 15(1):103-110. PubMed ID: 27909727
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of polyuridylic acid in human soft tissue and bone sarcomas.
Adepoju LJ; Geiger JD
J Surg Res; 2010 Nov; 164(1):e107-14. PubMed ID: 20828720
[TBL] [Abstract][Full Text] [Related]
12. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides.
Makovitzki A; Fink A; Shai Y
Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852
[TBL] [Abstract][Full Text] [Related]
13. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
Joyner DE; Albritton KH; Bastar JD; Randall RL
J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of human soft tissue sarcomas in xenografts and in vitro.
Ishii S; Yamawaki S; Saki T; Usui M; Ubayama Y; Minami A; Yagi T; Isu K; Kobayashi M
Clin Orthop Relat Res; 1983 Mar; (173):251-61. PubMed ID: 6297838
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-responsive oncolytic polypeptide for tumor therapy.
Yin R; Wan P; Guo Z; Yi X; Zhang P; Shen W; Chen L; Xiao C; Chen X
Acta Biomater; 2024 Jun; 181():415-424. PubMed ID: 38704115
[TBL] [Abstract][Full Text] [Related]
17. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Becerikli M; Merwart B; Lam MC; Suppelna P; Rittig A; Mirmohammedsadegh A; Stricker I; Theiss C; Singer BB; Jacobsen F; Steinstraesser L
Int J Cancer; 2015 Apr; 136(8):1781-91. PubMed ID: 25274141
[TBL] [Abstract][Full Text] [Related]
20. Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.
Casper ES; Christman KL; Schwartz GK; Johnson B; Brennan MF; Bertino JR
Cancer; 1993 Aug; 72(3):766-70. PubMed ID: 8392904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
